Immuno-oncology: what is next for AML?

The current role of immuno-oncology in AML and future outlooksПодробнее

EHA: AML immuno-oncology updatesПодробнее

Immune Checkpoint Inhibition in Myeloid MalignanciesПодробнее

What is immunotherapy for AML?Подробнее

Key challenges in immunotherapy for AMLПодробнее

Bob Löwenberg's perspective on CAR-T and immunotherapy for AMLПодробнее

Immuno-oncology and the future of multiple myeloma treatmentПодробнее

Immunotherapy in Acute Myeloid LeukemiaПодробнее

Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and moreПодробнее

The future of immuno-oncologyПодробнее

ImmunoOncology & Targeted Therapy: What's Next and What's NowПодробнее

Immunotherapy in AML: azacitidine plus checkpoint inhibitorsПодробнее

AML research at Dana-Farber: updates from Richard StoneПодробнее

Next questions in AMLПодробнее

Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapyПодробнее

Clinical trials of immune checkpoint inhibitors in acute myeloid leukemia (AML)Подробнее

The impact of immuno-oncology on ALL outcomesПодробнее

AML immunotherapy: patients need to be well informedПодробнее

Immuno-oncologyПодробнее